Effect Of Enkephalinase Inhibitor On Plasma Calcitonin Gene-related Peptide And Substance P In Patients With Chronic Heart Failure

Objective:Angiotensin receptor blockers/enkephalinase inhibitors(ARNI)are new drugs for the treatment of heart failure.However,what effect does it have on inflammatory factors(CGRP,substance P)in elderly patients with heart failure? Can it alleviate the progression of heart failure patients? It is still unclear Therefore,the purpose of this research is to explore the effects of enkephalinase inhibitor(ARNI)on serum concentrations of calcitonin gene-related peptide(CGRP)and substance P in patients with chronic heart failure,and its role in delaying the progression of heart failure.Methods:The chronic heart failure patients with a clear diagnosis and meeting the inclusion and exclusion criteria were selected.The patients were randomized into enkephalinase inhibitor treatment group(ARNI treatment group,n=30 cases,receiving ARNI treatment,3 months of treatment)and conventional treatment group(n=30 cases,receiving conventional anti-heart failure medicine treatment,3 months of treatment).Before starting the study,record the gender,age,smoking,and drinking of the two groups of patients,measured blood pressure,heart rate,measure albumin,creatinine,uric acid,blood lipid levels,troponin I and other indicators,and compared baseline data.All the participants underwent echocardiography examination at baseline and after treatment,and their serum levels of CGRP and substance P were determined.Results:Compared with those in conventional treatment group,patients in ARNI treatment group had higher serum CGRP levels(98.11±13.87pg/ml vs 68.92±16.54pg/ml),and lower substance P levels(2.71±0.76pg/ml vs4.33±0.77pg/ml),both the differences were statisticallysignificant(both P<0.01).The patients in ARNI treatment group had lower LVDD(56.86±5.81 VS 60.10±4.55mm)and LVDS(46.56±5.01 mm vs 49.86±4.68mm),and higher LVEF(37.90±4.88% vs 35.26±4.66%)than those in the conventional treatment group.All the differences were statistically significant(all P<0.05).Conclusion:ARNI can effectively regulate the serum levels of CGRP and substance P,delay ventricular remodeling,and improve cardiac function in patients with heart failure,which is worthy of clinical use.